Beyond the Thyroid: How Hashimoto's Damages the Gut and Starves You of Iron
11 min read · Uplevel editorial
Most people with Hashimoto's are told a simple story: the immune system attacks the thyroid, the thyroid slows down, you take levothyroxine, done. That story is incomplete in a way that matters. Hashimoto's is frequently a two-organ disease. The same autoimmune process that goes after the thyroid often goes after the stomach, and the stomach is where iron absorption lives or dies.
There is a common misconception worth correcting up front, because it inverts the mechanism. Stomach acid does not destroy iron absorption. The loss of stomach acid does. In Hashimoto's, the gut lesion that travels with the disease is autoimmune atrophic gastritis, and its defining feature is low acid production. When the acid goes, non-heme iron can no longer be absorbed. That single inversion explains a large share of the fatigue, hair loss, and stubborn "low ferritin" that thyroid patients live with even when their TSH looks controlled.
This piece walks the full mechanism, grades each claim by the strength of evidence behind it, and translates it into what actually changes in a workup.
The autoimmune cluster: why the stomach comes along
Hashimoto's rarely arrives alone. It sits inside a recognized constellation called autoimmune polyendocrine syndrome type III, in which autoimmune thyroid disease clusters with chronic atrophic gastritis, pernicious anemia, type 1 diabetes, and vitiligo. These conditions share a tendency to produce organ-specific autoantibodies, and the stomach is one of the most common second targets.
The stomach lesion is driven by antibodies against gastric parietal cells. Those cells run two production lines: the proton pump (the H+/K+ ATPase) that makes hydrochloric acid, and intrinsic factor, the protein required to absorb vitamin B12 later in the small intestine. Autoimmune gastritis destroys the cells, so both outputs fall together. In a clinical series of autoimmune thyroid patients screened for this, roughly a quarter carried anti-parietal cell antibodies, and among those, iron deficiency, B12 deficiency, and anemia were common findings rather than rare ones.
One detail reshapes how you interpret lab work: iron deficiency tends to appear first, often years before the classic B12-driven macrocytic anemia that people associate with the disease. Early autoimmune gastritis can show high parietal cell antibody titers and inflammation confined to the gastric body while the blood count still looks unremarkable. In practice, an unexplained or treatment-resistant iron deficiency in a Hashimoto's patient is frequently the earliest visible signal that the stomach is involved.
Why no acid means no iron
To understand the iron problem you have to follow the chemistry of a single mineral through the gut.
Non-heme iron, the kind in plants, supplements, and fortified foods, arrives mostly as ferric iron (Fe3+). Ferric iron is poorly soluble and cannot cross the intestinal wall. Before absorption, it has to be freed from the food matrix and chemically reduced to ferrous iron (Fe2+), which the DMT1 transporter in the duodenum can actually carry into the body. Gastric acid is what makes both steps possible. It dissolves the iron and creates the low-pH environment that supports its reduction, with dietary vitamin C and the brush-border enzyme Dcytb finishing the conversion.
Remove the acid and this pathway stalls. Iron stays locked as insoluble ferric complexes and passes straight through. This is also why the iron deficiency of atrophic gastritis is so often refractory to oral iron pills: the tablets rely on the same acid the patient no longer produces. It is a closed loop of failure, and it explains the patient who "takes iron every day" and stays deficient for years.
Heme iron, the form in red meat and other animal tissue, is absorbed by a separate route that is largely independent of stomach pH. That is why patients with low acid hold their iron better from animal-source food than from non-heme supplements, and it is a practical lever rather than a footnote.
There is one more consequence of chronic low acid worth naming, because it changes surveillance rather than supplementation. Persistent achlorhydria drives the stomach to overproduce the hormone gastrin, which over time expands enterochromaffin-like cells and raises the long-term risk of gastric carcinoid and adenocarcinoma. Persistent parietal cell antibody positivity is therefore a reason to consider endoscopic evaluation, not just an iron prescription.
The vicious loop: iron deficiency feeds the thyroid disease back
This is the part that elevates the gut lesion from comorbidity to amplifier.
Thyroid peroxidase, the enzyme that builds T4 and T3 by iodinating thyroglobulin, is a heme enzyme. It requires iron to function. So iron deficiency does not merely cause anemia downstream. It throttles thyroid hormone production at the source, inside the gland itself.
The population data track with the mechanism. A systematic review and meta-analysis found that iron-deficient individuals have significantly lower TSH, free T4, and free T3, that ferritin correlates positively with free T4, and that iron deficiency is associated with a higher prevalence of thyroid autoantibody positivity, including anti-TPO and anti-thyroglobulin. A separate systematic review focused on women with Hashimoto's argues, on exactly these grounds, that ferritin should be a standard part of the hypothyroidism workup rather than an afterthought.
Assemble the full circuit and the logic is uncomfortable but clean. Hashimoto's brings autoimmune gastritis. Gastritis removes acid. Lost acid starves iron absorption. Iron deficiency then cripples the iron-dependent enzyme the thyroid needs to make hormone, which deepens the hypothyroid state that started the cascade. The gut is not sitting downstream of the disease. It is feeding it.
The wider gut-thyroid axis
The stomach is the sharpest and most clinically actionable lesion, but the relationship between Hashimoto's and the gut is broader than acid and iron.
Dysbiosis and short-chain fatty acids. Hashimoto's patients show shifts in gut microbial composition, notably a depletion of the bacteria that produce butyrate. Butyrate feeds the cells lining the colon and helps maintain the balance between regulatory T cells and inflammatory Th17 cells. A 2024 human and mouse study found butyrate significantly reduced in Hashimoto's and linked that loss, partly modulated by iodine intake, to a Th17/Treg imbalance that favors autoimmunity. The human sample was small, so this is a plausible and biologically coherent signal rather than a settled fact.
Barrier dysfunction. A 2026 review describing the gut-thyroid axis frames increased intestinal permeability and Th17 activation as features shared across organ-specific autoimmunity, with the loss of barrier-supporting bacteria allowing antigenic material to provoke systemic immune activation. This is the mechanistic substrate behind the popular "leaky gut" language, though in humans the direction of causation is still largely observational.
Peripheral hormone handling and motility. Gut bacteria contribute to the peripheral conversion of T4 into active T3 and to the enterohepatic recycling of thyroid hormone, so dysbiosis can blunt the active hormone pool independent of the gland. Running the other direction, hypothyroidism slows gut transit, which drives constipation and predisposes to small intestinal bacterial overgrowth, closing yet another loop.
Celiac disease. This one deserves explicit naming. Celiac shares the HLA-DQ2 and DQ8 genetic susceptibility that underlies autoimmune thyroid disease, and it is markedly overrepresented in Hashimoto's. Its villous atrophy independently impairs iron absorption in the duodenum, giving a second, distinct route to iron deficiency that has nothing to do with gastric acid. In a Hashimoto's patient with unexplained iron deficiency, celiac and autoimmune gastritis are both on the table.
Evidence grading, claim by claim
Grades reflect the strength of the underlying evidence, not the confidence of the narrative. Physiology and biochemistry that are textbook-established are graded high even where disease-specific trials are thin, and observational or preclinical signals are graded honestly as such.
Grade key. A (High): meta-analyses, systematic reviews, or established human physiology. B (Moderate): cohort or case-control data, or a single systematic review with limitations. C (Low): small studies, case reports, observational associations with confounding, or extrapolation from preclinical models.
| # | Claim | Grade | Basis |
|---|---|---|---|
| 1 | Hashimoto's clusters with autoimmune atrophic gastritis within autoimmune polyendocrine syndrome type III | A | Clinical cohorts and screening series (Castoro 2016; Villanacci 2017) |
| 2 | Anti-parietal cell antibodies destroy parietal cells, removing both hydrochloric acid and intrinsic factor | A | Established pathophysiology; antibody and gastrin data (Castoro 2016; Kishino 2021) |
| 3 | Iron deficiency is often the earliest hematologic sign of autoimmune gastritis, preceding B12 deficiency | B | Case description plus cohort pattern (Kishino 2021; Villanacci 2017) |
| 4 | Gastric acid is required to solubilize and reduce non-heme iron (Fe3+ to Fe2+) for duodenal DMT1 absorption | A | Established gastrointestinal physiology and biochemistry |
| 5 | Iron deficiency from low acid is frequently refractory to oral non-heme iron | B | Clinical observation consistent with the absorption mechanism |
| 6 | Heme iron uptake is largely pH-independent, so animal-source iron is better retained when acid is low | A | Established physiology of the heme iron transport pathway |
| 7 | Chronic achlorhydria drives hypergastrinemia and ECL-cell hyperplasia, raising gastric carcinoid and adenocarcinoma risk | B | Cohort data plus established oncologic pathway (Castoro 2016) |
| 8 | Thyroid peroxidase is a heme (iron-dependent) enzyme; iron is required for thyroid hormone synthesis | A | Enzyme biochemistry (Adam 2025) |
| 9 | Iron deficiency is associated with lower TSH, FT4, and FT3 and higher thyroid autoantibody positivity | B | Systematic review and meta-analysis of cross-sectional studies, high heterogeneity (Garofalo 2023) |
| 10 | Ferritin should be assessed in Hashimoto's workup, not just hemoglobin | B | Systematic review recommendation (Gierach 2024) |
| 11 | Hashimoto's shows depletion of butyrate-producing taxa and reduced butyrate, tilting the Th17/Treg balance | C | Small human cohort plus mouse model (Gong 2024) |
| 12 | Increased intestinal permeability accompanies Hashimoto's and may promote systemic immune activation | C | Narrative reviews, observational, causal direction unclear (Ribacuka 2026; Legakis 2023) |
| 13 | Gut microbiota contribute to peripheral T4 to T3 conversion and enterohepatic thyroid hormone recycling | C | Mechanistic and review-level evidence (Legakis 2023) |
| 14 | Hypothyroidism slows gut transit, causing constipation and predisposing to bacterial overgrowth | B | Established motility effect; overgrowth association weaker |
| 15 | Celiac disease shares HLA-DQ2/DQ8 susceptibility with autoimmune thyroid disease and independently impairs iron absorption | A | Strong epidemiologic association plus established villous-atrophy mechanism |
| 16 | Atrophic gastritis and H. pylori raise levothyroxine dose requirements via pH-dependent absorption; oral iron chelates levothyroxine | B | Absorption studies and pharmacology (Ihnatowicz 2019) |
| 17 | Repleting iron improves fatigue and physical performance in iron-deficient women, including the non-anemic | A | Cochrane meta-analysis of 67 RCTs plus non-anemic low-ferritin trials (Low 2016; Pedrazzini 2009) |
| 18 | In non-anemic women, iron-related symptoms track with low ferritin — hair loss around ≤20 µg/L, restless legs around ≤50 — not a high threshold | B | Cross-sectional symptom–ferritin study (Beatrix 2021) |
| 19 | A ferritin target near 100 for symptom resolution is clinical convention, not a trial-established threshold | C | No supporting trial evidence; symptom associations sit lower |
What this changes in a workup
The mechanism is only useful if it changes decisions. Four practical shifts follow directly from it.
Test ferritin, not just hemoglobin. Iron deficiency depresses thyroid enzyme function long before it produces overt anemia, so a normal blood count does not rule it out. Ferritin, ideally with transferrin saturation, belongs in the standard Hashimoto's panel.
Treat refractory iron deficiency as a signal, not a dosing problem. When oral iron repeatedly fails, the next step is to look upstream at the stomach, with parietal cell antibodies, gastrin, and B12, rather than escalating a supplement that the gut cannot absorb.
Match the iron form to the acid environment. When acid is low, non-heme tablets underperform. Heme iron, co-administration with vitamin C, or intravenous repletion become the rational routes, and the choice should be deliberate rather than default.
Respect the levothyroxine interactions. The same atrophic gastritis and H. pylori that block iron also raise levothyroxine requirements through pH-dependent absorption, and oral iron chelates levothyroxine directly. Separate the two by several hours, and expect dose needs to shift if gastric status changes.
Does repleting iron help — and how high should ferritin go?
Fixing the iron is not academic; it changes how people feel. A Cochrane meta-analysis of 67 randomized trials in menstruating women found that daily iron not only corrects anemia and rebuilds iron stores but also improves exercise performance and reduces symptomatic fatigue, and separate trials show that even non-anemic women with low ferritin and unexplained fatigue can benefit from repletion. So the reason to test ferritin is not to fill in a lab value. It is that treating a genuine deficiency, once the absorption problem behind it is addressed, is one of the more reliably rewarding things you can do for energy in this population.
How high does ferritin need to go? Here the popular target deserves a caveat. The common claim that ferritin must reach a high number — often quoted as 100 — before symptoms resolve is not established by trials. The best data on symptoms in non-anemic women actually place the associations at low ferritin: recent hair loss tracks with ferritin at or below roughly 20 µg/L and restless legs at or below about 50, not at 100. The defensible goal is to move ferritin clearly and durably out of the deficient range and then re-check the specific symptom, rather than chase an arbitrary high number — and in a low-acid stomach that usually means heme iron, vitamin C co-administration, or intravenous repletion when oral tablets fail.
The through-line is simple. In Hashimoto's, treating the thyroid without checking the gut leaves the loop intact. The stomach is often where the fatigue actually comes from.
---
This article is for education and is not medical advice. Iron status, thyroid function, and gastric autoimmunity require individual evaluation and testing. Do not start, stop, or change any medication or supplement, including iron and levothyroxine, without a qualified clinician who can review your labs and history.
Uplevel members: your program includes a full iron and thyroid panel with gastric autoimmunity screening when indicated, read through a performance-medicine lens rather than a reference-range one.
References
Sources retrieved via PubMed. Access each through its DOI link.
- Castoro C, et al. Association of autoimmune thyroid diseases, chronic atrophic gastritis and gastric carcinoid: experience from a single institution. J Endocrinol Invest. 2016;39(7):779-84. DOI
- Villanacci V, et al. Autoimmune gastritis: relationships with anemia and Helicobacter pylori status. Scand J Gastroenterol. 2017;52(6-7):674-677. DOI
- Kishino M, et al. A case of early autoimmune gastritis with characteristic endoscopic findings. Clin J Gastroenterol. 2021;14(3):718-724. DOI
- Adam LN, Abbas AM. Thyroid peroxidase gene variants and autoimmunity in subclinical hypothyroidism: molecular mechanisms and clinical implications. Mol Biol Rep. 2025;52(1):1049. DOI
- Garofalo V, et al. Relationship between Iron Deficiency and Thyroid Function: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(22):4790. DOI
- Gierach M, Rudewicz M, Junik R. Iron and ferritin deficiency in women with hypothyroidism and chronic lymphocytic thyroiditis: systematic review. Endokrynol Pol. 2024;75(3):253-261. DOI
- Gong B, et al. Effects of iodine intake on gut microbiota and gut metabolites in Hashimoto thyroiditis-diseased humans and mice. Commun Biol. 2024;7(1):136. DOI
- Ribacuka S, et al. The Gut-Skin and Gut-Thyroid Axis in Autoimmunity. Nutrients. 2026;18(10):1501. DOI
- Legakis I, Chrousos GP, Chatzipanagiotou S. Thyroid Diseases and Intestinal Microbiome. Horm Metab Res. 2023;55(12):813-818. DOI
- Ihnatowicz P, et al. The importance of nutritional factors and dietary management of Hashimoto's thyroiditis. Ann Agric Environ Med. 2019;27(2):184-193. DOI
- Low MSY, Speedy J, Styles CE, De-Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev. 2016;4:CD009747. DOI
- Pedrazzini B, Waldvogel S, Vaucher P, et al. Iron supplementation in female blood donors with a decreased ferritin level and no anaemia. Trials. 2009;10:4. DOI
- Beatrix J, Piales C, Berland P, et al. Non-anemic iron deficiency: correlations between symptoms and iron status parameters. Eur J Clin Nutr. 2021;76(6):835-840. DOI
Frequently asked
Why does Hashimoto's cause iron deficiency?+
If I have Hashimoto's and low ferritin that will not come up on iron pills, what should I check?+
Does iron deficiency make hypothyroidism worse?+
Related reading